Itraconazole Sugar Free Syri

Itraconazole, the active ingredient in Itraconazole Sugar Free Syri, is an azole antifungal presented as an oral formulation for oral use. It treats a range of fungal infections, including skin, nail and systemic mycoses, and is commonly prescribed for dermatophytosis, onychomycosis and invasive systemic infections such as blastomycosis and histoplasmosis, in adult patients as directed by a healthcare professional.

GNH USA supplies Itraconazole Sugar Free Syri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, sourced from the European Union market.

Itraconazole is an azole antifungal used to treat infections caused by dermatophytes, yeasts and dimorphic fungi.

Dermatophytosis: eradicates skin fungal infections such as tinea corporis and tinea pedis. Onychomycosis: clears fungal nail infections, improving nail appearance and preventing spread. Systemic mycoses: treats invasive infections like blastomycosis, histoplasmosis, and other deep-seated fungal diseases. Candidiasis: manages mucosal and systemic Candida infections when other agents are unsuitable.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Abdominal discomfort or pain. - Headache. - Rash or mild skin irritation. - Altered taste sensation. - Diarrhea.

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Cardiac failure or congestive heart failure. - Visual disturbances or blurred vision. - QT interval prolongation leading to arrhythmias.

When prescribing itraconazole, clinicians should consider several safety measures.

Liver function monitoring: obtain baseline and periodic liver enzyme tests. Drug interaction review: assess concomitant medications for CYP3A4 involvement. Pregnancy risk: avoid use unless potential benefit justifies potential fetal risk. Renal impairment: evaluate need for dose adjustment in severe kidney disease. Avoid grapefruit juice: it can increase itraconazole plasma concentrations. Store at ambient temperature: keep in the original container, protect from moisture and light.

Itraconazole interacts with many agents; careful management is required.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: markedly reduce itraconazole exposure. - Ketoconazole or other azole antifungals: increase risk of hepatotoxicity. - Macrolide antibiotics (e.g., erythromycin): may raise itraconazole levels and toxicity. - St. John's wort: potent CYP3A4 inducer that lowers itraconazole concentrations. - Concurrent use with other QT‑prolonging drugs: heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy. - Warfarin: observe INR for possible anticoagulant effect changes. - Oral contraceptives: efficacy may be reduced; advise alternative contraception. - Antacids or H2‑blockers: may decrease absorption; separate dosing times. - Proton‑pump inhibitors: may modestly affect bioavailability; monitor clinical response.